Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 132% in the afternoon session after the company announced plans to make it easier for its members to access Eli Lilly's FDA-approved weight loss drug Zepbound. Given the success of weight loss drugs with regulatory approval and the crackdown on knock-offs, expanding the distribution of Zepbound should accelerate adoption. Additionally, companies such as WeightWatchers should benefit from increased sales volume and greater customer loyalty as they align themselves with medically endorsed treatments.
WW International shares are trading higher by 79% during Tuesday's session. The company announced a new partnership with Eli Lilly's LillyDirect pharmacy provider.
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising drug and healthcare costs.
A lawsuit claims Eli Lilly, Johnson & Johnson, and Kaiser Permanente failed to warn consumers about breast cancer risks linked to their antipsychotic drugs Risperdal and Zyprexa.
Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and will not address global pricing inequities.
HSBC noted that while the market has assumed a significant market share for Eli Lilly, these expectations may be revised in light of potential economic sensitivity to the adoption curve for weight loss drugs.
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south.
While some investors embrace risk, mistakes can be costly for those who aren’t prepared.
Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023.
Pfizer highlighted positive late-stage results for its experimental bladder cancer drug, sasanlimab, as it looks to strengthen its oncology portfolio and offset losses from recent setbacks in its weight-loss drug program.
Jim Cramer is preparing investors for another action-packed week on Wall Street, packed with earnings reports from major tech players and key economic updates.
